Analyst Brief April 14, 2026

H.R. 2319 — Women and Lung Cancer Research and Preventive Services Act of 2025

Executive Summary

H.R. 2319, the 'Women and Lung Cancer Research and Preventive Services Act of 2025,' directs the Secretary of Health and Human Services, in consultation with the DoD and VA, to conduct a comprehensive interagency review of lung cancer research focusing on women and underserved populations. Despite lung cancer being a leading cause of cancer death, significant knowledge gaps persist regarding its etiology in women—particularly non-smokers—and screening access for marginalized groups. The bill mandates a report to Congress within two years that identifies opportunities for innovative collaborative research, expanded national screening strategies, and public awareness campaigns to improve early detection and health outcomes.

Arguments For

  • Addresses a critical public health blind spot: the rising incidence of lung cancer in women, particularly non-smokers, which currently lacks sufficient targeted research.
  • Highly bipartisan appeal; it focuses on interagency coordination, research, and strategic planning rather than creating massive new mandatory spending programs.
  • Leverages existing federal infrastructure (HHS, VA, DoD) to improve screening access and early detection, which ultimately saves long-term healthcare costs by catching cancers at more treatable stages.

Likely Supporters

American Lung AssociationAmerican Cancer Society Cancer Action NetworkLUNGevity FoundationWomen's health advocacy organizations

Arguments Against

  • May be viewed by fiscal conservatives as duplicative of existing National Institutes of Health (NIH) or Centers for Disease Control and Prevention (CDC) research efforts.
  • Lacks direct funding appropriations, meaning agencies must absorb the administrative cost of the interagency review and report generation.
  • Creates an administrative mandate for a report without immediately expanding actual on-the-ground treatment services or clinical trial funding.

Likely Opponents

Minimal organized opposition expected

📋 Key Provisions

  • Mandates an interagency review by HHS, DoD, and VA to evaluate the status of lung cancer research specifically targeting women and underserved populations.
  • Requires the identification of opportunities for collaborative research to address knowledge gaps, evaluate environmental and genomic factors, and foster advancements in imaging technology.
  • Directs the development of recommendations for a national lung cancer screening strategy to expand access to preventive services.
  • Calls for the exploration of a national public education and awareness campaign emphasizing the importance of early detection.
  • Requires the HHS Secretary to submit a comprehensive report to Congress detailing the review's findings within two years of enactment.
search Verification Guide BETA expand_more

Don't trust AI? Don't worry, neither do I. Verify the claims yourself.

Claim Analysis Page 3, Line 14

Requires HHS to consult with the Secretaries of Defense and Veterans Affairs.

Verify Text

"Human Services, in consultation with the Secretary of De-"

Claim Analysis Page 3, Line 22

Focuses on underserved populations meeting USPSTF screening criteria.

Verify Text

"cancer screening as recommended by the United"

Claim Analysis Page 5, Line 10

Requires a report to Congress within two years of enactment.

Verify Text

"(c) REPORT.—Not later than two years after the date"